GlassScriptPhysician profile
Laura S Mueller
NPI 1902955313
$3,724.18
in general payments reported to CMS, 2019-2025
25 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $207 · 2021: $974 · 2022: $835 · 2023: $538 · 2024: $224 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $495.71 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $450.93 | 2020-2024 | Caplyta |
| Lundbeck LLC | $300.88 | 2019-2022 | |
| Alkermes, INC. | $273.75 | 2021-2024 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $242.28 | 2019-2022 | |
| Abbvie INC. | $222.24 | 2023-2025 | |
| Tris Pharma INC | $212.32 | 2019-2022 | |
| Neos Therapeutics, LP | $207.23 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $202.18 | 2019-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $168.42 | 2019-2024 | Spravato |
| Axsome Therapeutics, INC. | $163.38 | 2022-2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $146.01 | 2019-2023 | Austedo, Austedo Xr |
| Bausch Health US, LLC | $138.55 | 2020-2025 | Wellbutrin, Aplenzin |
| Corium, LLC | $94.79 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $72.95 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $56.63 | 2019 | |
| Neurocrine Biosciences, INC. | $50.96 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $42.57 | 2019 | |
| Alfasigma USA, INC. | $36.39 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $34.01 | 2021 | |
| Almatica Pharma LLC | $29.57 | 2024 | Loreev Xr |
| Adlon Therapeutics L.P. | $27.05 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $24.49 | 2019 | |
| Aytu Biopharma, INC. | $18.17 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.